金陵药业股份有限公司 2025第二次临时股东大会决议公告

Core Points - The second extraordinary general meeting of shareholders for 2025 was held on August 8, 2025, with no resolutions being rejected [1][2] - The meeting was conducted in compliance with relevant laws and regulations, ensuring the legitimacy of the proceedings and participants [3][17] Group 1: Meeting Details - The meeting took place at the company's headquarters in Nanjing, combining on-site and online voting methods [3][4] - A total of 200 shareholders attended, representing 302,220,749 shares, which is 48.4554% of the total voting shares [4][5] Group 2: Voting Results - The first resolution regarding the repurchase and cancellation of restricted stock received 99.8798% approval from attending shareholders [8][9] - The second resolution concerning changes to registered capital and amendments to the Articles of Association was approved with 99.8774% [11][12] - The third resolution for the appointment of additional non-independent directors was passed with 99.6078% support [14][15] Group 3: Legal Opinions - The legal opinion from Jiangsu Taihe Law Firm confirmed that the meeting's procedures and voting results were lawful and valid [17] Group 4: Stock Repurchase Announcement - The company announced a stock repurchase plan involving the cancellation of 178,410 shares due to non-compliance with the incentive plan [22] - The total repurchase cost was 6,075,789 yuan, funded by the company's own resources, resulting in a reduction of registered capital from 623,708,628 yuan to 621,924,528 yuan [22][24]